7Baggers

Evoke Pharma Quarterly Balance Sheets Chart

Quarterly
 | 
Annual
 
 Account Receivables  
 Cash and Cash Eq  
 Inventory  
20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220331 20220630 20220930 20221231 20230331 20230630 20230930 20231231 20240331 20240630 20240930 02.65.27.7910.3912.9915.5918.19Milllion

Evoke Pharma Quarterly Balance Sheets Table

Quarterly
 | 
Annual
 
Unit: USD2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2016-12-31 2015-12-31 2014-12-31 2013-12-31 
                                 
  assets                               
  current assets:                               
  cash and cash equivalents11,339,032 9,177,836 9,702,755 4,739,426 5,964,826 7,006,431 8,212,804 9,843,699 12,350,024 13,450,949 7,701,201 9,144,710 11,141,908 16,720,939 18,185,974 8,068,939 6,280,656 7,990,392 4,133,188 5,663,833 6,504,802 7,440,079 4,028,550 5,319,004 6,567,918 6,531,079 7,679,267 9,007,071 8,691,155 14,155,809 24,196,691 
  accounts receivable2,022,518 2,003,003 1,451,904 673,071 1,233,904 1,023,813 687,302 624,832 674,970 365,643 418,910 295,193 222,166 198,411 127,795 23,311                
  prepaid expenses146,704 382,936 704,215 885,040 37,855 371,348 671,386 952,954  307,919 615,832 923,746  307,254 614,508 921,762 336,432 193,902 387,803 581,706 775,607 109,739 219,479 329,218 438,957 83,682 251,046 267,711 833,276 931,461 234,262 
  inventories493,408 544,765 588,776                             
  other current assets36,421 27,675 6,312 47,532 98,094 11,551 11,551 11,551 11,551 11,551 11,551 11,551 11,551 11,703 11,703 30,300 11,551 11,551 11,551  11,551 11,551 11,551   11,551  7,997  161,436  
  total current assets14,038,083 12,136,215 12,453,962 6,826,909 7,839,604 8,926,855 9,947,910 11,722,414 13,256,849 14,404,396 9,026,270 10,560,734 11,600,842 17,472,348 19,176,024 9,280,792 6,714,784 8,195,845 4,532,542 6,245,539 7,291,960 7,561,369 4,259,580 5,648,222 7,006,875 6,626,312 7,930,313 9,282,779 9,524,431 15,248,706 24,430,953 
  deferred offering costs115,488   241,637                            
  total assets14,153,571 12,136,215 12,453,962 7,068,546 7,852,974 8,979,697 10,039,307 11,851,488 13,410,520 14,404,396 9,026,270 10,573,162 11,649,959 17,557,281 19,295,950 9,434,048 6,750,899 8,267,056 4,637,894 6,395,628 7,327,358 7,631,164 4,362,832 5,659,773 7,018,426 6,626,312 7,941,864 9,294,330 9,532,428 15,301,729 24,986,458 
  liabilities and stockholders' equity                               
  current liabilities:                               
  accounts payable and accrued expenses2,188,164 2,183,850 1,953,959 1,711,778 1,397,442 1,415,309 1,185,925 934,312 1,020,690 824,481 944,478 874,028 530,528 519,001 691,225 1,273,572 765,603 604,832 925,628 1,033,383 1,154,520 407,517 491,831 476,202 625,994 441,085 1,048,927 478,223 927,606 1,011,629 284,915 
  accrued compensation590,634 425,797 265,881 1,324,010 829,669 612,932 400,251 591,158 716,993 528,665 412,198 519,317 810,790 621,476 428,794 1,016,232 715,423 860,521 685,266 843,162 964,243 807,706 692,304 1,158,251 984,683 824,849 1,025,911 933,450 760,782 697,245 557,399 
  note payable5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 5,000,000 2,000,000 2,000,000              
  accrued interest payable1,987,637 1,861,610 1,736,953 1,612,295 1,486,268 1,360,240 1,235,583 1,112,295 986,268 860,240 735,583 612,295 486,268 360,240 235,583 112,994 53,005               
  total current liabilities9,766,435 9,471,257 8,956,793 3,035,788 2,240,481 2,081,083 1,677,573 1,654,544 1,877,983 1,353,146 1,356,676 1,405,773 1,390,435 6,231,435 6,248,983 7,535,677 6,621,309 6,640,732 1,716,246 2,015,083 2,154,161 1,285,018 1,287,387 1,634,453 1,610,677 1,265,934 2,074,838 1,411,673 1,834,440 1,871,617 2,284,906 
  total liabilities9,766,435 9,471,257 8,956,793 9,648,083 8,726,749 8,441,323 7,913,156 7,766,839 7,877,622 7,213,386 7,092,259 7,018,068 6,876,703 11,591,675 11,484,566 12,648,671 8,674,314 8,640,732      1,634,453 1,610,677 1,265,934 5,776,115 5,506,692 6,067,499 6,113,065 3,803,197 
  commitments and contingencies                               
  stockholdersʼ equity                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 as of september 30, 2024 and december 31, 2023; issued and outstanding shares — zero as of september 30, 2024 and december 31, 2023                               
  common stock89 73 859 334 334 334 334 334 334 334 3,292 3,266 3,266 3,244 3,237 2,662 2,633 2,601 2,446 2,443 2,423 2,411 1,788 1,743 1,743 1,690 1,541 1,235 720 611 610 
  additional paid-in capital131,985,913 128,951,361 128,515,568 120,859,567 120,577,928 120,296,170 120,016,030 119,731,458 119,376,486 119,020,734 111,527,397 110,974,841 110,520,641 109,743,561 109,298,703 95,667,776 94,691,151 94,111,817 90,439,901 90,108,492 89,482,936 89,027,832 83,643,658 82,628,312 82,250,109 80,683,323 73,202,863 62,595,546 51,524,821 45,127,202 43,874,119 
  accumulated deficit-127,598,866 -126,286,476 -125,019,258 -123,439,438 -121,452,037 -119,758,130 -117,890,213 -115,647,143 -113,843,922 -111,830,058 -109,596,678 -107,423,013 -105,750,651 -103,781,199 -101,490,556 -98,885,061 -96,617,199 -94,488,094 -87,520,699 -85,730,390 -84,312,162 -82,684,097 -80,570,001 -78,604,735 -76,844,103 -75,324,635 -71,038,655 -58,809,143 -48,060,612 -35,939,149  
  total stockholdersʼ equity4,387,136 2,664,958                              
  total liabilities and stockholders' equity14,153,571 12,136,215 12,453,962 7,068,546 7,852,974 8,979,697 10,039,307 11,851,488 13,410,520 14,404,396 9,026,270 10,573,162 11,649,959 17,557,281    8,267,056 4,637,894 6,395,628 7,327,358 7,631,164 4,362,832 5,659,773 7,018,426 6,626,312 7,941,864 9,294,330 9,532,428 15,301,729  
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 as of june 30, 2024 and december 31, 2023; issued and outstanding shares — zero as of june 30, 2024 and december 31, 2023                               
  stockholders' equity                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 as of march 31, 2024 and december 31, 2023; issued and outstanding shares — zero as of march 31, 2024 and december 31, 2023                               
  total stockholders' equity  3,497,169 -2,579,537 -873,775 538,374 2,126,151 4,084,649 5,532,898 7,191,010 1,934,011 3,555,094 4,773,256 5,965,606    -373,676 2,921,648 4,380,545 5,173,197 6,346,146 3,075,445 4,025,320 5,407,749 5,360,378 2,165,749 3,787,638 3,464,929 9,188,664  
  inventory   481,840 504,925 513,712 364,867 289,378 220,304 268,334 278,776 185,534 225,217 234,041 236,044 236,480 86,145               
  operating lease right-of-use asset    13,370 52,842 91,397 129,074 153,671   12,428 49,117 84,933 119,926 141,705 36,115 71,211 105,352 138,538 35,398 69,795 103,252         
  operating lease liability    13,370 52,842 91,397 129,074 140,300   12,428 49,117 84,933 119,926 141,705 36,115 71,211 105,352 138,538 35,398 69,795 103,252         
  long-term liabilities:                               
  total long-term liabilities   6,612,295 6,486,268 6,360,240 6,235,583 6,112,295 5,999,639 5,860,240 5,735,583 5,612,295 5,486,268 5,360,240 5,235,583 5,112,994 2,053,005               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2023 and 2023; issued and outstanding shares — 0 at december 31, 2023 and 2022 respectively                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at september 30, 2023 and december 31, 2022; none issued and outstanding at both september 30, 2023 and december 31, 2022                               
  stockholders' equity:                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at june 30, 2023 and december 31, 2022; issued and outstanding shares — 0 at june 30, 2023 and december 31, 2022 respectively                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at march 31, 2023 and december 31, 2022; issued and outstanding shares — 0 at march 31, 2023 and december 31, 2022 respectively                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2022 and 2021; issued and outstanding shares — 0 at december 31, 2022 and 2021 respectively                               
  long-term liabilities                               
  operating lease liability, non-current        13,371                       
  other assets               11,551    11,551    11,551 11,551  11,551 11,551 7,997 53,023 555,505 
  paycheck protection program loan               104,168 104,168 104,168              
  milestone payable             5,000,000 5,000,000 5,000,000 5,000,000 5,000,000              
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2021 and 2020; issued and outstanding shares — 0 at december 31, 2021 and 2020                               
  other current liabilities             6,025 9,038               12,313  
  liabilities and stockholders' (deficit) equity                               
  stockholders' (deficit) equity:                               
  total stockholders' (deficit) equity              7,811,384 -3,214,623 -1,923,415               
  total liabilities and stockholders' (deficit) equity              19,295,950 9,434,048 6,750,899               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2020 and 2019; issued and outstanding shares — 0 at december 31, 2020 and 2019                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2019 and 2018; issued and outstanding shares — 0 at december 31, 2019 and 2018                               
  warrant liability                          3,701,277 4,095,019    
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2018 and 2017; issued and outstanding shares — 0 at december 31, 2018 and 2017                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2017 and 2016; issued and outstanding shares — 0 at december 31, 2017 and 2016                               
  current portion of long-term debt                            146,052 150,430 1,442,592 
  long-term debt, net of current portion                            4,233,059 4,241,448 1,511,461 
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2016 and 2015; issued and outstanding shares — 0 at december 31, 2016 and 2015                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2015 and 2014; issued and outstanding shares — 0 at december 31, 2015 and 2014                               
  other long-term liabilities                               
  preferred stock, 0.0001 par value; authorized shares — 5,000,000 at december 31, 2014 and 2013; issued and outstanding shares — 0 at december 31, 2014 and 2013                               
  liabilities, convertible preferred stock and stockholders’ equity                               
  deferred rent expense                              6,830 
  series a convertible preferred stock, 0.0001 par value; authorized shares – 0 at december 31, 2013 and 12,305,068 at december 31, 2012; issued and outstanding shares – 0 at december 31, 2013 and 12,195,068 at december 31, 2012; liquidation preference – 0 at december 31, 2013 and 18,292,602 at december 31, 2012                               
  stockholders’ equity                               
  preferred stock, 0.0001 par value; authorized shares – 5,000,000 at december 31, 2013 and 0 at december 31, 2012; issued and outstanding shares – 0 at december 31, 2013 and 2012                               
  deficit accumulated during the development stage                              -22,691,468 
  total stockholders’ equity                              21,183,261 
  total liabilities, convertible preferred stock and stockholders’ equity                              24,986,458 

We provide you with 20 years of balance sheets for Evoke Pharma stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Evoke Pharma. Explore the full financial landscape of Evoke Pharma stock with our expertly curated balance sheets.

The information provided in this report about Evoke Pharma stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.